FDA Acknowledges Blocked Intestines in Ozempic Users, Updates Label

The US Food and Drug Administration (FDA) has updated the label of the diabetes drug Ozempic to acknowledge reports of blocked intestines in some users. Ozempic and its sister drug, Wegovy, have gained popularity for their ability to help people feel fuller longer. Drugmaker Novo Nordisk, the manufacturer of Ozempic and Wegovy, stated that patient safety is a priority and they are working closely with the FDA to monitor the safety profile of their medications. The labels of Wegovy and another diabetes drug, Mounjaro, also acknowledge reports of intestinal blockage. Some users have reported developing gastroparesis, but Novo Nordisk claims that gastrointestinal events are known side effects of GLP-1 agonists. A woman in Louisiana is suing Novo Nordisk and Eli Lilly over severe gastrointestinal events she claims were caused by using Ozempic and Mounjaro.